Africa Breast Cancer Therapeutics Market Report 2022 to 2030

Africa Breast Cancer Therapeutics Market Analysis

$ 3999

The Africa breast cancer therapeutics market is projected to grow from $273 Mn in 2022 to $801 Mn by 2030, registering a CAGR of 14.4% during the forecast period of 2022-2030. The main factors responsible for this market growth are the increasing prevalence of breast cancer cases and the rising demand for the treatment of breast cancer treatment in Africa. The market is segmented by therapy, by cancer type, and by distribution channel. Pfizer, Novartis, and Merck are some of the key players in the Africa breast cancer therapeutics market.

ID: IN10AFPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Africa AUTHOR: Parul Choudhary

Buy Now

Africa Breast Cancer Therapeutics Market Executive Analysis

The Africa breast cancer therapeutics market size is at around $273 Mn in 2022 and is projected to reach $801 Mn in 2030, exhibiting a CAGR of 14.4% during the forecast period. By 2030, it is predicted that Africa's healthcare market will be worth $259 Bn. Despite the fact that these patterns point to a profitable market potential for the private sector, an unregulated African healthcare system may result in more Africans living in poverty. One of the many flaws in Africa's health systems that the COVID-19 pandemic has shown is the continent's extremely high out-of-pocket (OOP) health expenses. In fact, despite the devastation the virus has caused, it has also given the continent opportunities to reshape both its supply systems and its health infrastructure, calling for a switch from donor and externally manufactured products to continental production systems by leveraging opportunities provided by the African Continental Free Trade Agreement.

Breast cancer is the most common disease in African women, and over the past three decades, its prevalence has progressively increased due to variables including increased longevity, a westernized lifestyle marked by later marriages, shorter breastfeeding periods, and younger menarche ages. Due to inadequate oncologic care, which includes palliation as well as prevention, mortality rates are greater and survival rates are lower in Africa than in developed nations. Africa has a greater incidence of triple-negative and hormone receptor-negative tumors. The observed lower survival rates compared to high-income countries are a result of a lack of oncology specialists, including nurses and surgeons, access to radiotherapy, availability of both traditional and contemporary systemic and hormonal therapies, and steadfast adherence to harmful socio-cultural beliefs. In the past, mastectomy was the only surgical procedure used to treat breast cancer (complete removal of the breast). Mastectomy may still be required for big malignancies. Most breast cancers can now be treated with a less invasive treatment called a lumpectomy or partial mastectomy, in which only the breast tumor is removed. In order to treat microscopic cancer that has spread from the breast tumor through the blood, breast cancer is frequently treated with a combination of surgical removal, radiation therapy, and hormonal therapy, chemotherapy, and/or targeted biological therapy.

africa breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

The fact that breast cancer is the most prevalent cancer worldwide will be a major factor in the growth of the Africa breast cancer therapeutics market. As more people are diagnosed with breast cancer in Africa, there is a growing demand for effective and precise therapy for those who have the disease. Future breakthrough therapies will be conceivable as a result of the leading market participants' strong tendency toward ongoing R&D in the field of breast cancer therapeutics.

Market Restraints

Advanced cancer therapeutics are costly to acquire, making it difficult for those with low-income levels to use them. Additionally, a significant barrier to the sale of manufacturers' goods is the absence of healthcare insurance in developing and poor countries. The Africa breast cancer therapeutics market may have difficulties in the near future due to low awareness regarding the availability of cancer medications caused by the lack of access to basic healthcare services in some areas.

Competitive Landscape

Key Players

F. Hoffmann-La Roche
Bristol-Myers Squibb
AbbVie
Johnson & Johnson
Celgene Corporation
Astellas Pharma
Pfizer
Novartis
Merck
Eli Lilly

Healthcare Policies and Regulatory Landscape

Depending on the nation and kind of insurance coverage, different countries in Africa have different breast cancer healthcare policies. In general, lack of infrastructure, restricted access to high-quality care, and high expenses can limit access to breast cancer therapy in many African nations. For example, in Nigeria, the expense of breast cancer treatment is covered by a combination of government-sponsored health insurance and private health insurance for patients. The extent of coverage varies between insurance companies and in Kenya, many patients rely on private health insurance to cover the expense of breast cancer treatment because the government only offers a little amount of health insurance coverage for residents.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.